Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)	Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, male reproductive system disorder, metastatic prostate carcinoma, prostate disorder	Recruiting	Phase 3	2024-12-20		NCT06496581

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis	114
UNICANCER	111

25 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Antoine Lacassagne	Nice	France	60
Centre Eugène Marquis	Rennes	France	37
Centre Francois Baclesse	Caen	France	19
Centre Georges-François Leclerc	Dijon	France	7
Centre Henri Becquerel	Rouen	France	71
Centre Léon Berard	Lyon	France	11
CHRU Brest	Brest	France	21
CHRU Nancy	Nancy	France	31
CHRU Tours	Tours	France	18
CHU Grenoble	Grenoble	France	48
CHU Henri Mondor	Créteil	France	18
CHU Rouen	Rouen	France	49
CHU Saint Etienne	Saint-Priest-en-Jarez	France	6
Gustave Roussy	Villejuif	France	47
Hôpital Cochin	Paris	France	34
Hôpital Saint Louis	Paris	France	21
ICANS	Strasbourg	France	10
Institut Bergonié	Bordeaux	France	47
Institut Curie	Saint-Cloud	France	12
Institut Curie	Paris	France	44
Institut de Cancérologie de l'Ouest	Angers	France	12
Institut de Cancérologie de l'Ouest	Saint-Herblain	France	17
Institut de Cancérologie de Lorraine	Vandœuvre-lès-Nancy	France	19
Institut Paoli-Calmettes	Marseille	France	23
IUCT Oncopole	Toulouse	France	7

Clinical trials